Skip to content
value.today

LogicBio Therapeutics, Inc.

Total raised
$33 M
2 rounds on record
Latest round
$29 M
Jun 2017
First round on record
Jan 2016
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of LogicBio Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2017$29 MNo. 2$10 to $50 million

LogicBio Therapeutics, Inc.: Raise no. 2, Jun 2017

Investors in this round

9 investors had bought by the notice of Jul 5, 2017: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for LogicBio Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$29 M of $45 M offered; $16 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Frederic A. Chereau · Executive Officer, Director
  • Marc A. Rubenstein · Executive Officer
  • Daniel A. O'Connell · Director
  • Erez A. Chimovits · Director
  • Leon A. Chen · Director
  • Mark A. Kay · Director
  • Sofia A. Ioannidou · Director
  • Tomer A. Kariv · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Frederic Chereau, Chief executive officer. Source: SEC Form D, newest notice filed Jul 5, 2017. Read the notice at the SEC.

equitySEC
Jan 2016$4 MNo. 1$2 to $10 million

LogicBio Therapeutics, Inc.: Raise no. 1, Jan 2016

Investors in this round

1 investor had bought by the notice of Jan 21, 2016: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for LogicBio Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $5 M offered; $1 M still to sell
Smallest investment taken
$1
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Adi Barzel · Executive Officer, Director
  • Leszek Lisowski · Executive Officer, Director
  • Erez A. Chimovits · Director
  • Mark A. Kay · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Leszek Lisowski, President. Source: SEC Form D, newest notice filed Jan 21, 2016. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • LogicBio Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2017).

    SEC Form D · Jul 2017

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Jul 2017

That is all the official record says: LogicBio Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

6 named in official filings. Open an investor to see everything it has backed.

Investors in LogicBio Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Arix Bioscience Holdings LtdCompanynot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Arix Bioscience PLCCompanynot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
OrbiMed Advisors Israel II LtdFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner, director (Form 3, 2018)SEC Form 3
Orbimed Advisors LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner, director (Form 3, 2018)SEC Form 3
OrbiMed Capital GP VI LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner, director (Form 3, 2018)SEC Form 3
OrbiMed Israel GP II, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner, director (Form 3, 2018)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 9 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by LogicBio Therapeutics, Inc.
NameRoleNamed in
Frederic A. ChereauExecutive officerJul 2017
Marc A. RubensteinExecutive officerJul 2017
Adi BarzelExecutive officerJan 2016
Leszek LisowskiExecutive officerJan 2016
Daniel A. O'ConnellDirectorJul 2017
Erez A. ChimovitsDirectorJul 2017
Frederic A. ChereauDirectorJul 2017
Leon A. ChenDirectorJul 2017
Mark A. KayDirectorJul 2017
Sofia A. IoannidouDirectorJul 2017
Tomer A. KarivDirectorJul 2017
Adi BarzelDirectorJan 2016
Leszek LisowskiDirectorJan 2016